Telix Pharma Jumps 5% as FDA Accepts Brain Cancer Drug NDA

Telix Pharmaceuticals' shares climbed after the US Food and Drug Administration accepted its New Drug Application for its brain cancer imaging agent, Pixclara®, setting a decision date of September 11, 2026.

The announcement was made by the company on Thursday, confirming the resubmitted application for Floretyrosine F 18, an investigational Positron Emission Tomography (PET) agent.

Pixclara® is designed to detect glioma, the most common and aggressive form of primary brain cancer. The acceptance of the NDA follows a previous refusal to file letter issued by the FDA, which the company has now addressed.

The FDA's acceptance is a significant step forward for Telix, de-risking the regulatory path for Pixclara® and boosting investor confidence. The decision moves the product closer to potential commercialization in the United States, a key market for oncology diagnostics.

The imaging agent, known chemically as 18F-FET, aims to provide a new diagnostic tool for neuro-oncology. Gliomas are notoriously difficult to manage, and improved imaging can aid in diagnosis, surgical planning, and monitoring treatment response.

Telix's stock, trading under the ticker TLX on both the ASX and NASDAQ, reacted positively to the news. The PDUFA (Prescription Drug User Fee Act) goal date marks the deadline for the FDA to review the new drug.

This regulatory milestone is a major validation of Telix's diagnostic pipeline and its ability to navigate complex regulatory hurdles. Investors will now be closely watching for the FDA's final decision on or before the September 11, 2026, PDUFA date, which could unlock a significant market opportunity in neuro-oncology imaging.

This article is for informational purposes only and does not constitute investment advice.